AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00493480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carvedilol
Description: 6.25 mg of carvedilol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubled weekly up to a maximum of 25 mg carvedilol daily.
Study NCT00493480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Description: 80 mg of propranolol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubles weekly up to a maximum of 360 mg propranolol daily
Study NCT00841672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 300/10 mg tablet
Description: Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
Study NCT00841672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 10 mg capsule
Description: Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
Study NCT02770677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Dantien Salee Yoga Training Program
Description: The intervention aims to improve pulmonary function and functional fitness.
Study NCT02649985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [F-18]PBR06
Description: PET radiopharmaceutical
Study NCT02649985 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [F-18]PBR06
Description: PET radiopharmaceutical
Study NCT02649985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]PBR06
Description: PET radiopharmaceutical
Study NCT02649985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [C-11]PBR28
Description: PET radiopharmaceutical
Study NCT01781741 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT)
Description: Undergo TEMLA and SBRT
Study NCT02077803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 100 mg
Description: Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
Study NCT01014767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard Arm, Cycle 2: 350 mg/m2 IV over 2 hours on day 2 and 3~All Arms, Cycles 4 \& 6: 350 mg/m2 IV over 2 hours on day 2 and 3
Study NCT02077803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR, 500 mg
Description: Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
Study NCT02077803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg
Description: Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 1, to be taken orally.
Study NCT01014767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cycles 1 \& 2: 70 mg/m²/d IV over 6 hours on day 4
Study NCT01014767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Standard Arm, Cycle 1: 1 g/m\^2 IV over 1 hour on day 2 and 3~All Arms, Cycles 3 \& 5: 1 g/m\^2 IV over 1 hour on day 2 and 3
Study NCT01014767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Cycles 1 \& 2: 45 µg/kg/day (max. 2 mg), IV on day 1
Study NCT01014767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Cycles 1 \& 2: 25 mg/m²/day IV over 12 hrs on days 1-3
Study NCT01014767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Standard Arm (1), Cycles 1 \& 2:~100 mg/m2 IV over 1 hour on days 1-5~All Arms, Cycles 4-6:~100 mg/m2 IV over 1 hour on days 1-5
Study NCT01014767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Temozolomide Irinotecan arm (4), Cycles 1 \& 2:~50 mg/m2/day x 5 days as 1 hour IV infusions
Study NCT01014767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given with Methotrexate as leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
Study NCT01014767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5g/m2 IV over 24 hours with leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
Study NCT01014767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 mg/m2/day x 5 days orally and combined with irinotecan 50 mg/m2/day IV x 5 days as one hour infusions.
Study NCT01014767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Standard Arm (1), Cycles 1 \& 2 : 1.5 mg/m\^2 IV over 15 minutes on day 5~Doxorubicin/cisplatin arm (2), Cycles 1 \& 2: 1.5 mg/m\^2/day (max. 2 mg), i.v. on days 8, 15~For all Groups, Cycles 3 - 6: 1.5 mg/m2 IV over 15 minutes on day 5
Study NCT06516081 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronutrient powder (Sprinkles®)
Study NCT06516081 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient powder (Sprinkles®)
Study NCT02869542 — intervention group
Intervention type: OTHER
Intervention: Data collection
Study NCT00285805 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rosiglitazone versus placebo
Study NCT00285805 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: response (sodium excretion) to amiloride infusion
Study NCT00285805 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: response (sodium excretion) to furosemide infusion
Study NCT03978000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IBP-9414
Description: Oral suspension
Study NCT03978000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water
Study NCT02563743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving based intervention
Description: The intervention comprises both the employee and the employer, and follows a clear structure comprising problem solving, stepwise activation and relapse prevention. It includes three meetings at the OHS with additional follow-ups.
Study NCT02563743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Study participants that are randomized into the control group will receive the usual care given at the OHS. This intervention will differ due to differences between the OHS units.
Study NCT03408483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block (QLB)
Description: Under ultrasound guidance, the needle will be advanced to the posterior border of the quadratus lumborum muscle. After negative aspiration, a bolus of 40 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected in 5 mL aliquots, ensuring proper placement of needle tip and appropriate spread of local anesthetic.
Study NCT03408483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: This is currently the standard of care, no local anesthetic will be injected. Pain will be managed with parenteral and oral medication.
Study NCT03799731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM102
Description: GM102 7 mg/kg weekly
Study NCT03799731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: Lonsurf 35 mg/m² twice daily during 10 days per cycle
Study NCT03799731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM102 expansion
Description: GM102 7 mg/kg weekly after a loading dose of 10 mg/kg q1w during 28-day cycle 1
Study NCT04688957 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oseodensification sinus lifting
Description: application of first densah bur with densifying mood (reverse) counterclockwise, 1200 revolution per minute until the sinus is reached then use a wider densah bur with the same mode and bouncing motion to elevate the sinus floor up to 3 mm in 1mm increments.
Study NCT04688957 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: osteotome sinus lifting
Description: drilling implant site with consecutive drills short of the sinus floor by 1-2mm , using osteotome in appropriate size and application of one tap until sinus floor is elevated, using the final drill for the desired implant diameter
Study NCT02250781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral ONC201
Description: Given PO
Study NCT02041884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT for Adults with ADHD
Description: A skill training internet-based treatment program based on CBT and DBT interventions .
Study NCT02041884 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet stress-reduction
Description: Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
Study NCT02041884 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual (TAU)/waiting list
Description: Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
Study NCT02318901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02318901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT02318901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ado-trastuzumab emtansine
Study NCT02318901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT01595334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix
Description: Cetrorelix 0.25 mg/d would be administered by subcutaneous injection to women when the plasma LH is higher (>4.5 mIU/ml) in the study arm
Study NCT01595334 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Luprolide Acetate
Description: Women in the control arm would receive Luprolide acetate 1 mg/day by subcutaneous injection
Study NCT04124042 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: plasmid DNA
Study NCT04124042 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: XT-150
Description: plasmid DNA
Study NCT04124042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a sterile phosphate-buffered saline
Study NCT01741441 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic total fundoplication
Description: LTF was performed using a standard five-trocar technique in all cases and carried out by two expert surgeons who had previously performed more than 50 laparoscopic fundoplications. A floppy 360° total fundoplication of 2-2,5 cm was constructed after full esophageal mobilization and posterior crural repair with nonabsorbable sutures.
Study NCT03767452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiaflex® 0.58 mg
Description: 0.25 mL injections.
Study NCT01946386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100 Aerosol, foam
Description: The products will be applied on 6 test sites (according to random assignment to specific test sites predetermined on their anterior face of forearms) for 6 hours
Study NCT01946386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate in LEO 90100 Aerosol, foam, vehicle
Study NCT01946386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100 Aerosol, foam, vehicle
Study NCT01946386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivobet® ointment
Study NCT01946386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermovate® cream
Study NCT01946386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synalar® ointment
Study NCT04850586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Group
Description: The patients in the training group were given structured training by a multidisciplinary team. After the content of the structured education was prepared, three experts were consulted for their opinions in terms of the scope and content. Necessary adjustments were made in line with their recommendations. Patients in this group were visited in their rooms at least 12 hours before undergoing surgery by a multidisciplinary team consisting of a surgeon, an anesthesiologist, and a nurse. The multidisciplinary team visited the patients at the same time and provided their education after introducing the team. Structured verbal education and written documents were given to the patients for 30 minutes on preoperative preparation, anesthesia, intubation, mobilization, deep breathing and coughing exercises, nutrition and fluid management, the postoperative recovery process, clinical practice guideline and operating room protocols.
Study NCT02035631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: The dietary component, aimed to reduce calorie intake according to individual requirements, will be structured in 1-hour weekly sessions led by trained nutritionists. Sessions will concentrate on teaching participants about food groups, the food pyramid and Mediterranean diet, how to chose, prepare and cook hypo-caloric meals.
Study NCT02035631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The physical activity component will include two sessions per week led by trained physical activity monitors including aerobic exercise of high/moderate intensity, and instruction about the at-home exercise activities (3 more sessions).
Study NCT02035631 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Minimal diet intervention
Description: Some basic diet recommendations
Study NCT02035631 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Minimal physical activity intervention
Description: Some basic recommendations on physical activity
Study NCT00087139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study NCT00073749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin [CMC-544]
Description: CMC-544, IV, dose escalation trial
Study NCT05643456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: 69 Patients with exotropia of (40-55) PD who are ≥ 5 years old. The 1st group 30 patients had two muscles surgery; bilateral lateral rectus recession.~The 2nd group 39 patients had three muscles surgery; bilateral lateral rectus recession and unilateral medial rectus tucking.
Study NCT02184806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthotopic graft
Description: (1) laparoscopy (2) ovarian fragments can be put back inside the pelvic cavity close to the natural location of the ovaries or
Study NCT02184806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: heterotopic graft
Description: 1. put under the skin~2. the ovarian fragments can be put under the skin of the abdomen
Study NCT02077803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg
Description: Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 2, to be taken orally.
Study NCT00683813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vCRP
Description: The vCRP includes online intake forms, one-on-one chat sessions with vCRP nurse, dietitian and exercise specialist, data collection (exercise heart rate, blood pressure, glucose- if diabetic), peer-support group chat sessions, ask-an-expert chat sessions, education, progress reports and online resources. VCRP patients will receive access to the website, a heart rate monitor and a blood pressure monitor and trained in their use. The heart rate monitors allow for exercise heart rate data to be stored and downloaded to their home computer and then uploaded to the vCRP webserver. The exercise data will be reviewed weekly. A letter to the patient's primary care physician will be sent to outline the vCRP intervention, the treatment algorithms to be used and indicate under what circumstances the vCRP nurse and/or patient may contact them with regards to their management. After the 4 month intervention, patients will be discharged into the care of their primary care physician.
Study NCT01293006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant
Description: one tablet (30 or 40 mg suvorexant depending on participant age: 40 mg for participants \<65 years of age and 30 mg for participants ≥65 years of age), orally, once daily, for 4 consecutive days
Study NCT01293006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: one tablet matching suvorexant, orally, once daily, for 4 consecutive days
Study NCT01781741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01751672 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SBIRT
Description: Screening, Brief Intervention, and Referral to Treatment. Standard, single session SBIRT.
Study NCT01751672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT+
Description: Expanded Screening, Brief Intervention, and Referral to Treatment. One Standard SBIRT session, plus 2-6 additional Brief Intervention sessions as needed.
Study NCT00869635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 Chemotherapy
Description: S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, \<1.25m2: 80mg/day, 1.25\~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment
Study NCT01193894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Profermin
Description: Medical Food (food for special medical purposes)
Study NCT02626364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crenolanib
Description: single-agent crenolanib at 100 mg PO TID
Study NCT04291924 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamometry
Description: A test for maximal muscle strength and explosive power in the lower limbs
Study NCT00525785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 2.2 Gm/m\^2 By Vein Over 48 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 300 mg/m2 a day Monday through Friday, by continuous infusion during radiation through an outpatient portable pump.
Study NCT00525785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: 200 mg/m\^2 by vein Over 30 Minutes On Days 1, 15, 29, and 43.
Study NCT00525785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100 mg/m\^2 By Vein Over 2 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 45 mg/m\^2 over 2 hours weekly for 5 weeks during radiation. (oxaliplatin should be administered on the first day of the radiation week).
Study NCT00525785 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45 Gy (1.8 Gy fx/day) Monday through Friday, 12 days after the last dose of 5FU plus oxaliplatin and no later than 28 days.
Study NCT00525785 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: 4-6 weeks after completion of chemoradiotherapy, restaged \& surgical resection of the primary tumor and lymph nodes attempted.
Study NCT04374201 — intervention group
Intervention type: OTHER
Intervention: 2 zirconia FDPs
Description: The United States Public Health Service criteria were used in order to examine technical and esthetic outcomes. Success and survival rates of the zirconia FDPs were calculated. The biological examination was performed analyzing both abutments and contralateral teeth.
Study NCT04374201 — intervention group
Intervention type: OTHER
Intervention: 1 zirconia FDP
Description: The United States Public Health Service criteria were used in order to examine technical and esthetic outcomes. Success and survival rates of the zirconia FDPs were calculated. The biological examination was performed analyzing both abutments and contralateral teeth.
Study NCT04478110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interactive group education, navigation services and engagement of health care providers for referrals, and linkage to care.
Description: The interactive group education was aimed to increase participant overall understanding of CRC, screening methods, and utilization of available resources such as home test kit and navigation services, with the ultimate goal of increasing screening rates. Clinical partners provided clinical support and ensured successful screening assessment and follow-ups by offering more flexible hours of clinic operation with bilingual medical staff on site. Patient navigation assistance was also offered based on participants' needs. The range of assistance included scheduling appointments with clinical partners for sigmoidoscopy/colonoscopy for screening and diagnosis after a FIT positive result, assisting paper.